Rivaroxabán (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rivaroxabán" in Spanish language version.

refsWebsite

Global rank Spanish rank

4^th place

2^nd place

6^th place

5^th place

low place

2,036^th place

57^th place

3^rd place

418^th place

5,011^th place

archive.org

Roehrig S, Straub A, Pohlmann J, et al (2005). «Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor». J. Med. Chem. 48 (19): 5900-8. PMID 16161994. doi:10.1021/jm050101d.
Eriksson BI, Borris L, Dahl OE, et al (2006). «Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement». J. Thromb. Haemost. 4 (1): 121-8. PMID 16409461. doi:10.1111/j.1538-7836.2005.01657.x.
Connolly, Stuart J.; Karthikeyan, Ganesan; Ntsekhe, Mpiko; Haileamlak, Abraham; El Sayed, Ahmed; El Ghamrawy, Alaa; Damasceno, Albertino; Avezum, Alvaro et al. (15 de septiembre de 2022). «Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation». The New England Journal of Medicine 387 (11): 978-988. ISSN 1533-4406. doi:10.1056/NEJMoa2209051. Consultado el 10 de enero de 2023.
Hampton T (2006). «New oral anticoagulants show promise.». JAMA 295 (7): 743-4. PMID 16478891. doi:10.1001/jama.295.7.743.

Connolly, Stuart J.; Karthikeyan, Ganesan; Ntsekhe, Mpiko; Haileamlak, Abraham; El Sayed, Ahmed; El Ghamrawy, Alaa; Damasceno, Albertino; Avezum, Alvaro et al. (15 de septiembre de 2022). «Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation». The New England Journal of Medicine 387 (11): 978-988. ISSN 1533-4406. doi:10.1056/NEJMoa2209051. Consultado el 10 de enero de 2023.

Roehrig S, Straub A, Pohlmann J, et al (2005). «Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor». J. Med. Chem. 48 (19): 5900-8. PMID 16161994. doi:10.1021/jm050101d.
ROCKET AF Study Investigators (2010). «Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.». Am Heart J 159 (3): 340-347.e1. PMID 20211293.
Eriksson BI, Borris L, Dahl OE, et al (2006). «Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement». J. Thromb. Haemost. 4 (1): 121-8. PMID 16409461. doi:10.1111/j.1538-7836.2005.01657.x.
Hampton T (2006). «New oral anticoagulants show promise.». JAMA 295 (7): 743-4. PMID 16478891. doi:10.1001/jama.295.7.743.

Connolly, Stuart J.; Karthikeyan, Ganesan; Ntsekhe, Mpiko; Haileamlak, Abraham; El Sayed, Ahmed; El Ghamrawy, Alaa; Damasceno, Albertino; Avezum, Alvaro et al. (15 de septiembre de 2022). «Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation». The New England Journal of Medicine 387 (11): 978-988. ISSN 1533-4406. doi:10.1056/NEJMoa2209051. Consultado el 10 de enero de 2023.